Abstract: Poster Presentations |

Study of Cardiovascular and its Hemodynamic Effects of PEG (Polyethylene Glycol) in Rat Model FREE TO VIEW

Mohammad R. Movahed, MD; Seyed Ahmad Samsam Shariat, M.D.*; Mehrnoosh Hashemzadeh, Ph.D.
Author and Funding Information

University of California, Irvine, Irvine, CA


Chest. 2004;126(4_MeetingAbstracts):826S. doi:10.1378/chest.126.4_MeetingAbstracts.826S-a
Text Size: A A A
Published online


PURPOSE:  PEG (Poly Ethylene Glycol) is a solvent and used in a wide range of biomedical applications including use in research as a precipitating agent for proteins and other macromolecules. Many fatty acid based molecules cannot be administered without a solvent in vivo. PEG can be employed to dissolve compounds to make them water soluble and usable. However, the effect of PEG on cardiovascular system has not been studied. The goal of this study is to test the effect of PEG on cardiovascular system in rat models.

METHODS:  All the experiments have been performed on two groups of male S-D rats weighing 250–300 g. The control group (10 rats) were subjected to intraperitonealy (IP) with 0.5 ml of 5% D/W in normal saline and the second group (6 rats) with PEG 400, 2 ml/Kg Ip, twice a day for one week. After 4 week under general anesthesia, a 1.4 French ultra miniature Pressure/Volume catheter was placed in left ventricle via right carotid artery to measure comprehensive hemodynamic changes. The data was acquired with Aria-1 Conductance System and analyzed with PVAN pressure-volume analysis software.

RESULTS:  All the systolic and diastolic parameters were similar in both groups except peripheral arterial elastance (Ea) which was decreased in PEG group. There were no significant differences in maximum (dp/ dtmax), and minimum (dp/dtmin) development of pressure stroke work, cardiac out put, ejection fraction, Vmax (maximum LV volume during cardiac cycle), Vmin (minimum LV volume during cardiac cycle), end systolic volume (Ves), end diastolic volume, dv/ dtmax, dv/dtmin and the peripheral arterial elastance (Ea).

CONCLUSION:  We have demonstrated that PEG as a solvent, decreases arterial elastance in rat models in comparison to placebo. Therefore PEG as a solvent should be used cautiously in cardiovascular research.

CLINICAL IMPLICATIONS:  PEG may effect Arterial Elastance and should be used causiously in cardiovascular reasearch. HR/ minVmaxVminPmaxSVEF%CO micl/minSW mmhg*miclEA mmhg/micldp/dt max mmhg/secdv/dt max micl/secCONTROL259.7218.686.71137.8211.9765.243085.131292.712.318087.83324.98PEG261.5121.837.97131.2813.8664.883570.761407.58.779042.86367.77P Value0.910.280.490.300.260.930.190.590.010.890.41

DISCLOSURE:  S. Samsam Shariat, None.

Wednesday, October 27, 2004

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543